Skip to main content
. Author manuscript; available in PMC: 2022 Aug 1.
Published in final edited form as: Biochim Biophys Acta Rev Cancer. 2021 May 31;1876(1):188572. doi: 10.1016/j.bbcan.2021.188572

Figure 2.

Figure 2.

An independent non-prospective clinical trial dataset (DFCI) confirms a sub-population of responder and non-responder to SCT stratified by CHEK1. Patients with high expression of CHEK1 appeared to have a smaller stem cell transplant effect on PFS.